Details of the Drug

General Information of Drug (ID: DMOWLVG)

Drug Name
Nitazoxanide
Synonyms
Alinia; Colufase; Cryptaz; Daxon; Heliton; Nitazoxanid; Nitazoxanida; Nitazoxanidum; Taenitaz; Tizoxanide glucuronide; AZT + Nitazoxanide; Alinia (TN); Annita (TN); Azt+ nitazoxanide; Daxon (TN); Dexidex (TN); Kidonax (TN); Nitax (TN); Nitazox (TN); Nitazoxanida [INN-Spanish]; Nitazoxanide [USAN:INN]; Nitazoxanidum [INN-Latin]; Pacovanton (TN); Paramix (TN); Phavic-1; Zox (TN); Nitazoxanide (USAN/INN); Daxon, Dexidex, Kidonax, Pacovanton, Paramix, Nitax, Zox, Nitazoxanide
Indication
Disease Entry ICD 11 Status REF
Clostridioides difficile infection 1A04 Approved [1]
Cryptosporidium infection 1A32 Approved [1]
Diarrhea DA90 Approved [2]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 3 [3]
Giardiasis N.A. Investigative [1]
Therapeutic Class
Antiparasitic Agents
Affected Organisms
Helminthic MicroorganismsEscherichia coliBacteria and protozoaMycobacterium tuberculosis
ATC Code
P01AX11: Nitazoxanide
P01AX: Other agents against amoebiasis and other protozoal diseases
P01A: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES
P01: ANTIPROTOZOALS
P: ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 307.28
Logarithm of the Partition Coefficient (xlogp) 2
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 7
ADMET Property
Bioavailability
70% of drug becomes completely available to its intended biological destination(s) [4]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 46.49 micromolar/kg/day [5]
Chemical Identifiers
Formula
C12H9N3O5S
IUPAC Name
[2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl] acetate
Canonical SMILES
CC(=O)OC1=CC=CC=C1C(=O)NC2=NC=C(S2)[N+](=O)[O-]
InChI
InChI=1S/C12H9N3O5S/c1-7(16)20-9-5-3-2-4-8(9)11(17)14-12-13-6-10(21-12)15(18)19/h2-6H,1H3,(H,13,14,17)
InChIKey
YQNQNVDNTFHQSW-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
41684
ChEBI ID
CHEMBL1401
CAS Number
55981-09-4
UNII
SOA12P041N
DrugBank ID
DB00507
TTD ID
D08EBN
ACDINA ID
D00473
Drug-Molecule Activity Atlas (DMA)NEW Click to Jump to the Detailed DMA Information of This Drug
Drug Pharmacogenomic Perturbation (DPP)NEW Click to Jump to the Detailed DPP Information of This Drug
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cryptosporidium Pyruvate:ferredoxin oxidoreductase (Crypto CpPNO) TT0F5P8 PNO_CRYPV Modulator [6]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Cyclic AMP-dependent transcription factor ATF-4 (ATF4) OTRFV19J ATF4_HUMAN Gene/Protein Processing [7]
Dedicator of cytokinesis protein 8 (DOCK8) OTNQLL21 DOCK8_HUMAN Drug Response [8]
Eukaryotic translation initiation factor 2A (EIF2A) OTWXELQP EIF2A_HUMAN Post-Translational Modifications [7]
Nuclear receptor subfamily 1 group I member 3 (NR1I3) OTS3SGH7 NR1I3_HUMAN Gene/Protein Processing [9]
Slit homolog 3 protein (SLIT3) OTU8MKEU SLIT3_HUMAN Drug Response [8]
Sushi domain-containing protein 6 (SUSD6) OTZS4SKF SUSD6_HUMAN Drug Response [8]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Nitazoxanide (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Glibenclamide DM8JXPZ Moderate Increased plasma concentration of Nitazoxanide and Glibenclamide due to competitive binding of plasma proteins. Acute diabete complication [5A2Y] [10]
Tolazamide DMIHRNA Moderate Increased plasma concentration of Nitazoxanide and Tolazamide due to competitive binding of plasma proteins. Acute diabete complication [5A2Y] [10]
Glipizide DMZA5PQ Moderate Increased plasma concentration of Nitazoxanide and Glipizide due to competitive binding of plasma proteins. Acute diabete complication [5A2Y] [10]
Clorazepate DMC3JST Moderate Increased plasma concentration of Nitazoxanide and Clorazepate due to competitive binding of plasma proteins. Anxiety disorder [6B00-6B0Z] [11]
Oxazepam DMXNZM4 Moderate Increased plasma concentration of Nitazoxanide and Oxazepam due to competitive binding of plasma proteins. Anxiety disorder [6B00-6B0Z] [10]
Diazepam DM08E9O Moderate Increased plasma concentration of Nitazoxanide and Diazepam due to competitive binding of plasma proteins. Epilepsy/seizure [8A61-8A6Z] [10]
Flurazepam DMAL4G0 Moderate Increased plasma concentration of Nitazoxanide and Flurazepam due to competitive binding of plasma proteins. Insomnia [7A00-7A0Z] [10]
Quazepam DMY4D87 Moderate Increased plasma concentration of Nitazoxanide and Quazepam due to competitive binding of plasma proteins. Insomnia [7A00-7A0Z] [10]
Estazolam DMZGXUM Moderate Increased plasma concentration of Nitazoxanide and Estazolam due to competitive binding of plasma proteins. Insomnia [7A00-7A0Z] [10]
Methotrexate DM2TEOL Moderate Increased plasma concentration of Nitazoxanide and Methotrexate due to competitive binding of plasma proteins. Leukaemia [2A60-2B33] [10]
Midazolam DMXOELT Moderate Increased plasma concentration of Nitazoxanide and Midazolam due to competitive binding of plasma proteins. Mood/affect symptom [MB24] [10]
Warfarin DMJYCVW Moderate Increased plasma concentration of Nitazoxanide and Warfarin due to competitive binding of plasma proteins. Supraventricular tachyarrhythmia [BC81] [10]
Tolbutamide DM02AWV Moderate Increased plasma concentration of Nitazoxanide and Tolbutamide due to competitive binding of plasma proteins. Type 2 diabetes mellitus [5A11] [10]
Chlorpropamide DMPHZQE Moderate Increased plasma concentration of Nitazoxanide and Chlorpropamide due to competitive binding of plasma proteins. Type 2 diabetes mellitus [5A11] [10]
⏷ Show the Full List of 14 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
FD&C blue no. 2 E00446 2723854 Colorant
Quinoline yellow WS E00309 24671 Colorant
Sunset yellow FCF E00255 17730 Colorant
Magnesium stearate E00208 11177 lubricant
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Saccharose E00091 5988 Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Soybean lecithin E00637 Not Available Other agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
⏷ Show the Full List of 9 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Nitazoxanide 500 mg tablet 500 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Nitazoxanide FDA Label
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 ClinicalTrials.gov (NCT04382846) Novel Regimens in COVID-19 Treatment. U.S. National Institutes of Health.
4 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
7 The anti-hepatitis C agent nitazoxanide induces phosphorylation of eukaryotic initiation factor 2alpha via protein kinase activated by double-stranded RNA activation. Gastroenterology. 2009 Nov;137(5):1827-35. doi: 10.1053/j.gastro.2009.07.056. Epub 2009 Aug 4.
8 Population-based in vitro hazard and concentration-response assessment of chemicals: the 1000 genomes high-throughput screening study. Environ Health Perspect. 2015 May;123(5):458-66. doi: 10.1289/ehp.1408775. Epub 2015 Jan 13.
9 Identification of Modulators That Activate the Constitutive Androstane Receptor From the Tox21 10K Compound Library. Toxicol Sci. 2019 Jan 1;167(1):282-292. doi: 10.1093/toxsci/kfy242.
10 Product Information. Alinia (nitazoxanide). Romark Laboratories L.C., Tampa, FL.
11 Guo LQ, Yamazoe Y "Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines." Acta Pharmacol Sin 25 (2004): 129-36. [PMID: 14769198]